Spexis AG (SIX:SPEX) is a clinical-stage, publicly-listed biopharmaceutical company focused on discovering and developing first-in-class macrocyclic molecules for rare diseases and cancers. The most advanced of our four clinical candidates (Phases 1-3) is ColiFin®, an inhaled therapeutic for cystic fibrosis, is already approved and marketed in Europe and will be entering global pivotal P3 studies in early 2023. Furthermore, we apply our leading macrocyclic technology platform, the result of more than 25 years and $400 million of cumulative research and investment, to discover promising therapeutic candidates that can target difficult-to-drug structures. With our pipeline of potentially transformative product candidates, we aim to deliver substantial benefits to patients and meaningful value to society and our stakeholders.

Spexis is seeking development, commercialization, strategic transaction and financial partners for its rare disease and oncology programs and the Company.